Cytokinetics to Announce Topline Results from ACACIA-HCM, the Pivotal Phase 3 Clinical Trial of Aficamten in Patients with Non-Obstructive Hypertrophic Cardiomyopathy, on May 5, 2026
Go back to Cytokinetics to Announce Topline Results from ACACIA-HCM, the Pivotal Phase 3 Clinical Trial of Aficamten in Patients with Non-Obstructive Hypertrophic Cardiomyopathy, on May 5, 2026| CYTOKINETICS (NASDAQ: CYTK) | Delayed: 70.15 +0.88 (1.27%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $69.27 | 52 Week High | $13.18 | |||
| Open | $69.74 | 52 Week Low | $6.00 | |||
| Day High | $71.25 | P/E | N/A | |||
| Day Low | $69.06 | EPS | $-1.24 | |||
| Volume | 1,292,938 | |||||
